





NUCLEAR CARDIOLOGICAL  
SOCIETY OF INDIA



# Cardiac Imaging Update 2017



**GN Mahapatra • PC Manoria • Diwakar Jain**



## SECTION 1: Cardiac Imaging

### NONINVASIVE

<b>1. Echocardiographic Evaluation of Infective Endocarditis: The Current Status</b>	<b>3</b>
<i>IB Vijayalakshmi</i>	
• Evaluation of Infective Endocarditis	3
<b>2. The Intricacies in Echocardiographic Evaluation of Aortic Stenosis</b>	<b>17</b>
<i>Sameer Shrivastava, Neel Bhatia</i>	
• Main Echocardiographic Indices Used to Assess AS Severity	17
• Aortic Valve Area	19
• Dimensionless Velocity Index	19
• Assessing Left Ventricle Contractile and/or Flow Reserve	20
• Distinguishing between True Severe and Pseudosevere Aortic Stenosis	21
<b>3. Echocardiography of Heart Failure: How to Use It in Routine Clinical Practice?</b>	<b>24</b>
<i>Satoshi Nakatani</i>	
• How to Assess Systolic Function of the Heart?	24
• How to Assess Diastolic Function of the Heart?	25
• Left Ventricular Geometry and Abnormal Echoes	28
• Right Ventricular Function	28
• Intracardiac Pressure Estimation	29
<b>4. Speckle Tracking Echocardiography: Basics and Clinical Applications</b>	<b>31</b>
<i>Navin C Nanda</i>	
• Cardiac Muscle Structure	31
• Methods of Speckle Tracking Echocardiography and Parameters Measured	32
<b>5. A Gold Standard for Evaluation of Cardiomyopathies</b>	<b>43</b>
<i>Johann Christopher</i>	
• Idiopathic Dilated Cardiomyopathy	43
• Myocarditis	43
• Hypertrophic Cardiomyopathy	44
• Restrictive Cardiomyopathy	45
• Cardiac Amyloidosis	45
• Arrhythmogenic Right Ventricular Cardiomyopathy	46
• Left Ventricular Noncompaction	46
• Myocardial Sarcoidosis	46
• Iron Overload Cardiomyopathy	46
<b>6. Real World Indications for Cardiac Magnetic Resonance Imaging: When is It Invaluable in Clinical Practice?</b>	<b>51</b>
<i>Tommaso D' Angelo, Eike Nagel</i>	
• Myocarditis	52
• Nonischemic Dilated Cardiomyopathies	53
• Hypertrophic Cardiomyopathy	53
• Coronary Artery Disease	54
• Viability/Hibernation	55
• Other Indications	55
• Contraindications and Limitations	55
<b>7. Cardiac MRI and Cardiac CT: Indispensable Tools for the Diagnosis of Coronary Artery Disease</b>	<b>57</b>
<i>Parang Sanghavi, Aamish Kazi, Bhavin Jankharia</i>	
• Cardiac Computed Tomography	57
• Cardiac Magnetic Resonance Imaging	59

<b>8. Cardiac Imaging: Current Scenario and Future Directions</b>	<b>61</b>
<i>Om Tavri, Priya Chudgar</i>	
<ul style="list-style-type: none"> <li>• Computed Tomography Coronary Angiography 61 • Perfusion Imaging 62</li> <li>• Virtual Computed Tomography—Fractional Flow Reserve 63 • Spectral Computed Tomography 63 • Plaque Characterization 63 • Hybrid Imaging 64</li> <li>• Cardiac Magnetic Resonance Imaging 64 • T1 and T2 Mapping 65</li> </ul>	
<b>9. Clinical Decision-making with Myocardial Perfusion Imaging in Patients with Known or Suspected Coronary Artery Disease</b>	<b>67</b>
<i>Mythri Shankar</i>	
<ul style="list-style-type: none"> <li>• Diabetes Mellitus 68 • Women and Elderly 68 • Chronic Kidney Disease 69</li> </ul>	
<b>10. Current Status of Rubidium-82 PET-CT Myocardial Perfusion Imaging</b>	<b>70</b>
<i>Prasanta Kumar Pradhan, Gowri Sankar</i>	
<ul style="list-style-type: none"> <li>• Historical Perspective 70 • Characteristics of Sr-82/Rb-82 Generator and Physiology of Rb-82 70 • Comparison with SPECT Agents 70 • Comparison between Rb-82 and N-13 Ammonia 71 • Dosimetry 71</li> </ul>	
<b>11. Innovation of New Tracers in the Era of Multimodality Cardiac Imaging</b>	<b>74</b>
<i>Padmakar V Kulkarni</i>	
<ul style="list-style-type: none"> <li>• Myocardial Function 75 • Myocardial Perfusion 75 • Fluorine-18-labeled Agents for Myocardial Perfusion Studies 75 • Energy Metabolism 76</li> <li>• Imaging Atherosclerotic Plaques 76</li> </ul>	
<b>12. Myocardial Imaging Products' Evolution: Change for the Better</b>	<b>80</b>
<i>N Ramamoorthy, Meera Venkatesh</i>	
<ul style="list-style-type: none"> <li>• Thallium-201 as Myocardial Perfusion Marker 80 • Technetium-99m Compounds as Myocardial Perfusion Markers 81 • Labeled Fatty Acid as Marker for Metabolism: Iodine-123 Products 81 • PET Tracers as Myocardial Perfusion Markers 81</li> <li>• PET Tracers as Marker of Myocardial Viability 82</li> </ul>	
<b>13. Efficacy of Combining FDG-PET Metabolic and Tc-99m–MIBI Myocardial Perfusion Study in Assessment of Myocardial Viability</b>	<b>85</b>
<i>BK Das, Sudatta Ray, Oma Shankar</i>	
<ul style="list-style-type: none"> <li>• What is Myocardial Viability? 85 • Methods of Assessment of Viability 85</li> <li>• Combination of MPS with MIBI and FDG-PET 86</li> </ul>	
<b>14. Myocardial Viability Assessment: Is it Alive?</b>	<b>88</b>
<i>Shrikant Solav</i>	
<b>15. Hybrid Myocardial Imaging Techniques: Role in Functionally Relevant Coronary Disease</b>	<b>90</b>
<i>Sanjay Gambhir, Mudalsha Ravina, Gawri Sankar, Nitin Yadav</i>	
<ul style="list-style-type: none"> <li>• Morphology Versus Anatomy 90 • Technical Developments 90</li> <li>• Calcium Scoring and Myocardial Perfusion Imaging 91 • Hybrid PET-MR 96</li> </ul>	
<b>16. Role of Coronary Flow Reserve in Coronary Artery Disease</b>	<b>100</b>
<i>Ashwani Sood, Abhiram GA, BR Mittal</i>	
<ul style="list-style-type: none"> <li>• Diagnosis of Coronary Artery Disease 100</li> </ul>	

- 17. Nuclear Medicine in Assessment of Cardiac Dyssynchrony** 106  
*Anirban Mukherjee, Chetan D Patel*
- Introduction to Cardiac Dyssynchrony 106
  - Nuclear Medicine Techniques in Assessment of Cardiac Dyssynchrony 106
  - Clinical Utility of Assessment of Cardiac Mechanical Dyssynchrony 108

## INVASIVE

- 18. Is Optical Coherence Tomography Ready to Replace Intravascular Ultrasound in Percutaneous Coronary Intervention?** 112  
*Debabrata Dash*
- Role of Optical Coherence Tomography before Percutaneous Coronary Intervention 112
  - Optical Coherence Tomography in Assessment of Stenting 114
  - Postintervention Assessment 114
  - Artifacts 115
  - Will Optical Coherence Tomography Replace Intravascular Ultrasound 115

- 19. Association of Coronary Stenosis and Plaque Morphology with Fractional Flow Reserve and Outcomes** 117  
*Jagat Narula*
- Severity of Luminal Stenosis and Fractional Flow Reserve 117
  - Plaque Morphology and Fractional Flow Reserve 118
  - Fractional Flow Reserve and Subsequent Clinical Events 119
  - Plaque Morphology: A Link between Fractional Flow Reserve and Clinical Outcomes 119
  - Article Information 122

## SECTION 2: Clinical Cardiology

### EMERGING THERAPIES

- 20. PCSK9 Inhibitors: Will they be the Next Wonder Drug after Statins?** 127  
*PC Manoria, Pankaj Manoria, Piyush Manoria, SK Parashar*
- Residual Atherogenic Risk Poststatin Therapy 127
  - High Triglycerides as a Determinant of Residual Atherogenic Risk 128
  - PCSK9 128
  - Clinical Approval in Europe and USA 130
- 21. Fighting the Devil of Stroke in Atrial Fibrillation: The New Weapons in the Armory** 134  
*PC Manoria, Pankaj Manoria, Piyush Manoria, SK Parashar*
- When to Use New Oral Anticoagulants? 135
  - Limitations of New Oral Anticoagulants 136
  - Comparison of TSOACs 140

### CORONARY ARTERY DISEASE

- 22. Management of Prehospital Phase of Acute Myocardial Infarction** 142  
*AK Pancholia*
- Pathophysiology and Impact of Time 142
  - Delays in Providing Treatment for Cardiac Emergencies 143
  - Prehospital ECGs in Patients with STEMI: What are the Benefits? 143
  - Current Guidelines for Prehospital ECGs among Patients with ST-segment Elevation Myocardial Infarction 144
  - Treatment of Acute Coronary Syndromes in the Prehospital Phase 145
  - Reperfusion Therapy: Prehospital Thrombolysis 146
  - Prerequisites for Prehospital Thrombolysis 146
  - Choice of Thrombolytic Agents for Prehospital Thrombolysis 146
  - Prehospital versus In-hospital Thrombolysis 147
  - Comparison of Thrombolysis with Percutaneous Coronary Intervention in Randomized Controlled Trials 147



- 23. STEMI Care in India and the Real World: Pharmacoinvasive Approach** **153**  
*HK Chopra*  
 • Development of Thrombolytic Therapy 153 • Trends in Thrombolysis for STEMI 156 • STEMI Care in India: Problems and Solutions 159  
 • Future Directions for STEMI Program in India 160
- 24. Bioresorbable Vascular Scaffold** **163**  
*MS Hiremath*  
 • Polymer Based 164 • Metal Based 164 • Cohort A 164 • E-BVS Implantation: Tips and Traps 165 • Role of Intravascular Imaging in BVS Implantation and Follow-up 167  
 • E-BVS from Clinical Trials to Clinical Practice 167 • Noninvasive Assessment of BVS 168  
 • Restoration of Vasomotion 168
- 25. Statin Intolerance** **174**  
*Peeyush Jain, Col. Viney Jetley*  
 • Statin Myopathy 174 • Common Concerns Associated with Long-term Use of Statins 174
- 26. Sudden Cardiac Death: How to Predict and Prevent it?** **182**  
*Pankaj Manoria, PC Manoria, Piyush Manoria*  
 • Magnitude of the Problem 182 • Causes of Sudden Cardiac Death 182  
 • Mechanism of Sudden Cardiac Death 182 • Risk Factors for Sudden Cardiac Death 183 • Treatment 183
- 27. New Gadgets Knocking at the Door: Leadless Pacemakers, Subcutaneous Implantable Cardioverter Defibrillators, Wearable Defibrillators** **187**  
*Anitha G, Ulhas M Pandurangi*  
 • Leadless Pacemaker 187 • Wireless Cardiac Stimulation System 187  
 • Subcutaneous Implantable Cardioverter Defibrillator 188  
 • Wearable Cardioverter Defibrillator 189
- 28. Echocardiographic Evaluation of Left Atrial Clot and Its Utility in Clinical Practice** **191**  
*Asha Moorthy, Jain T Kallarakkal*
- 29. Clinical Applications of Nuclear Cardiology Procedures and Its Future Directions** **193**  
*GN Mahapatra*  
 • Scope of Radionuclide Imaging Procedures 193 • Myocardial Perfusion 194  
 • Stress-gated SPECT Tc-99m Myocardial Perfusion Imaging Agents 195  
 • Clinical Applications of Myocardial Perfusion Imaging 197 • Pharmacological Stress Perfusion Imaging 199 • Dipyridamole Myocardial Perfusion Imaging 199  
 • Mechanism of Action of Dipyridamole 200 • Adenosine Myocardial Perfusion Imaging 200 • Dobutamine Myocardial Perfusion Imaging 200 • Pharmacological Stress Perfusion Imaging with Low Level Treadmill/Bicycle Exercise 202 • New Options in Pharmacological Stress 202 • Regadenoson Myocardial Perfusion Scintigraphy 202  
 • Dual Isotope Imaging Using Tl-201 and F-18 FDG Imaging 208 • Fluorodeoxyglucose Positron Emission Tomography versus Fluorodeoxyglucose Single Photon Emission Computed Tomography 210 • Emerging Concepts in Nuclear Cardiology 211  
 • Computation of Myocardial Blood Flow with Rubidium-82 and Comparison to N13 Ammonia 212 • Dynamic Single Photon Emission Computed Tomography (SPECT) 215  
 • F-18 Flurpiridaz Positron Emission Tomography Myocardial Perfusion Imaging Tracer 217

- F-18 BMS Myocardial PET Tracer 218
- C-11 Hydroxyephedrine/C-11 Epinephrine/I-123 MIBG and Tc99m tetrofosmin/Sestamibi SPECT MPI 218
- Tracers for Detecting Chronic Inflammatory Disorders such as Cardiac Sarcoidosis/Amyloidosis 218
- Tracers for Detecting Atheromatous Plaque Particularly Vulnerable Plaque Imaging 219
- Tracers for Stem Cells Tracking 219
- Tracers for Patients with Infectious Endocarditis and Aortic Graft Prosthetic Infection 219
- Useful Combined Nuclear Cardiology Techniques 221

### **30. Cardiac Positron Emission Tomography Perfusion Tracers: Current Status and Future Directions**

225

*Jamshid Maddahi, René RS Packard*

- Current Myocardial Perfusion Positron Emission Tomography Tracers 225
- Future Directions 226
- Funding 228
- Disclosure 228

*Index*

231

# 2

## The Intricacies in Echocardiographic Evaluation of Aortic Stenosis

Sameer Shrivastava, Neel Bhatia

In the developing world, aortic stenosis (AS) represents as one of the most prevalent valvular heart disease. Severe aortic stenosis is transformation of the aortic valve in a severely restricted, thickened, calcific valve; however, the initiating process is less likely to be a degenerative one, but rather similar to atherosclerotic plaque formation.

In the last few years more efforts have been put to predict aortic valve events more accurately. Today aortic stenosis patients are older and have been found to have higher incidence of hypertension, coronary disease, and diastolic dysfunction. Thus, the proportion of patients with low stroke volume due to left ventricular systolic function, small chamber size, increased vascular (in addition to valvular) afterload, and due to impaired longitudinal shortening may represent one-third of cases.<sup>1</sup>

Echocardiography has become the main diagnostic tool in assessing AS patients (**Table 1**). Beyond gradient and area values, it provides a comprehensive assessment of the aortic valve and aortic root morphology, which is of interest when planning the surgery, and of coexistent cardiac pathologies (**Table 1**). It is also instrumental in assessing special subgroups of patients with low gradients or decreased LV contractility, or those who may be considered for AVR even if asymptomatic. The central role of echocardiography in the management of AS patients is acknowledged by the use of echocardiographic indices to define AS severity and indications for surgery.<sup>2</sup>

### MAIN ECHOCARDIOGRAPHIC INDICES USED TO ASSESS AS SEVERITY

#### Flow Velocities and Gradients

- Both peak flow velocity ( $V_{max}$ ) and mean gradient are obtained by Doppler interrogation of aortic flow. As such, good alignment of the Doppler line and the flow direction ( $<20^\circ$ ) is required for accurate and reproducible results.

**Table 1** Echocardiographic information in aortic stenosis patients

<b>AV morphology:</b> <ul style="list-style-type: none"> <li>• Tricuspid or bicuspid</li> <li>• Severity of calcification</li> </ul>
<b>Aortic stenosis severity:</b> <ul style="list-style-type: none"> <li>• Gradient</li> <li>• Valve area</li> </ul>
<b>Aortic stenosis severity follow-up and progression of LV systolic function:</b>
Global (LVEF)
LV contractile reserve
Severity of LV hypertrophy
Response to exercise
Aortic dimensions and pathology
Co-existent valvular disease

Abbreviations: LV, left ventricle; LVEF, left ventricular ejection fraction

- $V_{max}$  is used rather than peak gradient to minimize the effect of small variations of velocity readings on the final result; this is less of a problem for the mean gradient that is obtained by integrating all the instantaneous gradients generated during ejection and is not a simple computation of mean velocity. For valvular jet velocities ( $V_2$ )  $>3$  m/s and subvalvular velocities ( $V_1$ )  $<1.5$  m/second, the latter can be ignored (simplified Bernoulli equation:  $\Delta P = 4V_2^2$ ), otherwise, both the proximal and the distal velocities have to be used (full Bernoulli equation). Furthermore, the cut-off values mentioned in **Table 2** are valid, if the LV ejection fraction (LVEF) is normal and there is no severe regurgitation across the valve.

Table 2 Stages of valvular aortic stenosis<sup>33</sup>

Stage	Definition	Valve anatomy	Valve hemodynamics	Hemodynamic consequences
<b>A</b>	At risk of AS	<ul style="list-style-type: none"> <li>Bicuspid aortic valve (or other congenital valve anomaly)</li> <li>aortic valve sclerosis</li> </ul>	Aortic $V_{\max} < 2$ m/s	None
<b>B</b>	Progressive AS	<ul style="list-style-type: none"> <li>Mild to moderate leaflet calcification of a bicuspid or trileaflet valve with some reduction in systolic motion or</li> <li>Rheumatic valve changes with commissural fusion</li> </ul>	<ul style="list-style-type: none"> <li>Mild AS: Aortic <math>V_{\max}</math> 2.0–2.9 m/s or mean pressure <math>&lt; 20</math> mm Hg</li> <li>Moderate AS: Aortic <math>V_{\max}</math> 3.0–3.9 m/s or mean pressure 20–39 mm Hg</li> </ul>	<ul style="list-style-type: none"> <li>Early LV diastolic dysfunction may be present</li> <li>Normal LVEF</li> </ul>
<b>C: Asymptomatic Severe AS</b>				
<b>C1</b>	Asymptomatic Severe AS	Severe leaflet calcification or congenital stenosis with severely reduced leaflet opening	Aortic $V_{\max} \geq 4$ m/s or mean pressure $\geq 40$ mm Hg • AVA typically is $< 1.0$ cm <sup>2</sup> (or AVAi $< 0.6$ cm <sup>2</sup> /m <sup>2</sup> ) Very severe AS is an aortic $V_{\max} > 5$ m/s or mean pressure $> 60$ mm Hg	<ul style="list-style-type: none"> <li>LV diastolic dysfunction</li> <li>Mild LV hypertrophy</li> <li>Normal LVEF</li> </ul>
<b>C2</b>	Asymptomatic Severe AS with LV dysfunction	Severe leaflet calcification or congenital stenosis with severely reduced leaflet opening	Aortic $V_{\max} > 4$ m/s or mean pressure $> 40$ mm Hg AVA typically $< 1.0$ cm <sup>2</sup> (or AVA $< 0.6$ cm <sup>2</sup> /m <sup>2</sup> )	LVEF $< 50\%$
<b>D: Symptomatic Severe AS</b>				
<b>D1</b>	Symptomatic severe high gradient AS	Severe leaflet calcification or congenital stenosis with severely reduced leaflet opening	Aortic $V_{\max} > 4$ m/s or mean pressure $> 40$ mm Hg AVA typically $< 1.0$ cm <sup>2</sup> (or AVA $< 0.6$ cm <sup>2</sup> /m <sup>2</sup> ) but may be larger with mixed AS/AR	<ul style="list-style-type: none"> <li>LV diastolic dysfunction</li> <li>LV hypertrophy</li> <li>pulmonary hypertension may be present</li> </ul>
<b>D2</b>	Symptomatic severe low-flow/low gradient AS with reduced LVEF	Severe leaflet calcification or congenital stenosis with severely reduced leaflet opening	AVA $< 1.0$ cm <sup>2</sup> with resting aortic $V_{\max}$ 4 m/s or mean pressure $< 40$ mm Hg Dobutamine stress echocardiography shows AVA $< 1.0$ cm <sup>2</sup> with $V_{\max} > 4$ m/s at any flow rate	<ul style="list-style-type: none"> <li>LV diastolic dysfunction</li> <li>LV hypertrophy</li> <li>LVEF <math>&lt; 50\%</math></li> </ul>
<b>D3</b>	Symptomatic Severe low gradient AS with normal LVEF or paradoxical low-flow severe AS	Severe leaflet calcification or congenital stenosis with severely reduced leaflet opening	AVA $< 1.0$ cm <sup>2</sup> with aortic $V_{\max} < 4$ m/s or mean DP $< 40$ mm Hg • Indexed AVA $< 0.6$ cm <sup>2</sup> /m <sup>2</sup> and • Stroke volume index $< 35$ mL/m <sup>2</sup> • Measured when patient is normotensive (systolic BP $< 140$ mm Hg)	<ul style="list-style-type: none"> <li>Increased LV relative wall thickness               <ul style="list-style-type: none"> <li>– Small LV chamber with low stroke volume</li> <li>– Restrictive diastolic filling</li> <li>– LVEF <math>\geq 50\%</math></li> </ul> </li> </ul>

### Sources of Error for Gradient Calculations

- Gradient underestimation is due to:
  - Malalignment of the Doppler line with the main flow direction; and
- Missing the transducer position/window providing the optimal signal.
- Gradient overestimation is due to–
  - Confusion with a different, higher-velocity systolic flow (mitral regurgitation [MR], LV outflow tract [LVOT])



obstruction); and inclusion of a beat following a long diastole in measurements.

### AORTIC VALVE AREA

Aortic valve area (AVA) is usually calculated using the continuity equation. All modern echocardiographic machines have incorporated analysis software to calculate AVA from the traced VTI and the measured LVOT diameter (**Fig. 1**). An alternative method to obtain the AVA is by direct planimetry of the valve orifice in parasternal short-axis view, using either transthoracic or transesophageal echocardiography (TEE).


### Sources of Error for Aortic Valve Area Calculations

The continuity equation method is subject to gradient error calculations and inaccurate LV outflow tract measurements, for which inter- and intra-observer variability may reach 8%.<sup>2</sup> This dimension, being squared in the continuity equation formula, can result in significant error and underestimation of valve area. The direct planimetry of the aortic valve orifice requires

good-quality images, occasionally available only with TEE. Even with TEE, aortic valve direct planimetry may be inaccurate with a heavily calcified valve and is therefore considered to be an acceptable alternative when Doppler measurements are unreliable, but it is not a primary method to assess AVA.

### DIMENSIONLESS VELOCITY INDEX

It is ratio between subvalvular (LVOT level) and valvular peak velocities, it is a version of the continuity equation that ignores LVOT diameter and thus is not subject to errors related to its measurements. A dimensionless velocity index (DVI)  $<0.25$  is indicative of severe AS, with a valvular area of 25% of the expected normal valve area for the patient's body size. DVI does not provide a valve area but rather confirms or weakens the qualitative diagnosis of severe AS. The velocity index is also useful to differentiate between high valvular gradients due to truly severe AS and mild AS with increased velocities due to high-flow conditions such as sepsis or hyperthyroidism, when the DVI remains  $>0.3$  as both the valvular and subvalvular velocities are high.



**Fig. 1:** Severe aortic stenosis by continuity equation

## Real Dilemmas in the Diagnosis of Aortic Stenosis

The limitations and possible errors described above are generally well-known and, although occasionally confusing, their avoidance by appropriate technique and awareness is expected from a good echo study.

The echocardiographic uncertainties one may encounter in the diagnosis of AS relate mainly to contradictory results and lack of concordance between accepted echocardiographic indices of AS severity or between echocardiographic and catheterization results. The challenge of appropriate quantification of AS in patients with decreased LV function is well recognized. However, even patients with good LV contractility exhibit a mixture of hemodynamic patterns. In their review of 3,483 echocardiographic studies of patients with various degrees of AS and normal EF, Minners, et al. found in 30% of cases a lack of concordance between the different criteria of AS severity. Moreover,  $V_{\max}$  and gradient were in the range of severe AS in 40–45% of patients, while by AVA 69–76% of them were diagnosed as having severe AS.<sup>3</sup>

Aortic stenosis severe by gradient but mild to moderate by aortic valve area. Occasionally, high (>4 m/s) peak velocities and elevated mean gradients (>30–40 mm Hg) are found in patients whose AVA by continuity equation is only in the mild to moderate range (>1 cm<sup>2</sup>).

Frequently, the reasons for this discordance are related to execution errors of the echocardiographic study:

- Incorrect positioning of the pulsed-wave Doppler sample volume too close to the aortic valve, so that the LVOT signal is contaminated by the high-velocity valvular flow; and
- Erroneous measurement resulting in overestimation of the LVOT diameter. Real discrepancies, i.e. high velocities and gradients in the absence of significant AS, can occur in patients with a high cardiac output state, such as sepsis, hyperthyroidism, anemia or with AV fistulas. Awareness of the patient's clinical condition and a DVI >0.25 should clarify this condition. Aortic stenosis mild to moderate by gradient but severe by aortic valve area faced with this discrepancy, the first step is to establish the contractility of the left ventricle and dichotomise these low-gradient severe AS patients into those with reduced or normal EF.

### Low-flow-Low-gradient Aortic Stenosis (LF/LGAS) with LV Systolic Dysfunction

It is defined as a combination of AVA <1 cm<sup>2</sup> (0.6 cm<sup>2</sup>/m<sup>2</sup>), mean gradient <40 mm Hg and LVEF <40%, and is described in 5–10% of patients with AS.<sup>4,5</sup> can be present in AS patients as a result of either concomitant pathology (coronary artery disease or cardiomyopathy) or of long-standing severe AS.

Other criteria which have been proposed in the literature to define the LF state in AS, include a cardiac index 3.0 L/min/m<sup>2</sup> and a stroke volume index 35 mL/m<sup>2</sup>.<sup>2,16,22</sup>

Given that the gradient essentially depends on the flow per beat (i.e. the stroke volume) rather than on the flow per minute (i.e. the cardiac output), the former is the most frequently used parameter in this context.<sup>22,25–27</sup>

The main diagnostic challenge in LF-LGAS with low LVEF is to distinguish true severe from pseudosevere AS.

In the former, the primary culprit is deemed to be the valve disease, and the LV dysfunction is a secondary or concomitant phenomenon. Conversely, the predominant factor in pseudosevere AS is deemed to be myocardial disease, and AS severity is overestimated due to incomplete opening of the valve in relation to the LF state. Distinction between these two entities is essential because patients with true severe AS generally benefit from aortic valve replacement (AVR), whereas those with pseudosevere AS may not benefit.

### ASSESSING LEFT VENTRICLE CONTRACTILE AND/OR FLOW RESERVE

The term “flow reserve” is utilized rather than “contractile reserve” because several mechanisms not necessarily related to intrinsic contractility may contribute to the lack of stroke volume increase during DSE, including: (1) afterload mismatch due to an imbalance between the severity of the stenosis and myocardial reserve;<sup>29</sup> (2) inadequate increase of myocardial blood flow due to associated CAD; and/or (3) irreversible myocardial damage due to previous myocardial infarction or extensive myocardial fibrosis.

deFilippi et al.<sup>15</sup> were the first to demonstrate that low-dose dobutamine stress echocardiography (DSE) may be used in these patients to assess the presence of LV flow reserve and to distinguish true versus pseudo severe aortic stenosis and to risk-stratify the patient in terms of perioperative risk and possible benefit of AVR. The use of DSE for this purpose has received a Class IIa (Level of Evidence: B) recommendation in the American College of Cardiology/American Heart Association-European Society of Cardiology (ACC/AHA-ESC/EACTS) guidelines.<sup>22–24</sup>

The accepted approach is to perform low-dose dobutamine stress echo study (DSE) and to quantify the inotropic response and the changes in AVA and transvalvular gradient.

### Dobutamine Stress Echo Study in Low-gradient Aortic Stenosis

The accurate assessment of aortic valve area in patients with a reduced stroke volume is difficult because the calculated valve area is proportional to stroke volume and the constant of the Gorlin equation varies with transvalvular flow.<sup>12,13</sup> As a result, some patients with AS and a low transvalvular pressure gradient have a reduced valve area because of inadequate stroke volume in the presence of thickened valve leaflets rather than a fixed, anatomic stenosis. Cannon et al.<sup>14</sup> described 8 such patients who were identified as having severe AS using

**Table 3** Hemodynamic response patterns to dobutamine in patients with low-flow-low-gradient aortic stenosis

Increase in stroke volume	Gradient	Aortic valve area	Conclusion
>20%	↔	Increased >1–1.2 cm <sup>2</sup>	Contractile reserve present, pseudo-severe AS
>20%	Increased	↔	Contractile reserve present, true severe AS
<20%	↔	↔	No contractile reserve ? AS

↔ = no significant change

the Gorlin equation but only mild AS during inspection of the valve at the time of surgery. These individuals were thought to have “pseudo-AS”; i.e., their aortic valve had thickened leaflets, which opened in direct relation to systolic blood flow. If the stroke volume was small, the leaflets opened poorly, resulting in a demonstrable transvalvular pressure gradient and a small calculated valve area. As the stroke volume increased, the leaflets opened more effectively, resulting in a larger valve area.

Dose of dobutamine required is in range of 5–20 µ/kg/minute, and although the dose-response to dobutamine is unpredictable and the inotropic response does not necessarily parallel the chronotropic and blood pressure response,<sup>6</sup> an increase in heart rate is generally taken as proof of dopaminergic stimulation sufficient to elicit an inotropic response. CR is considered to be present if the dobutamine infusion results in ≥20% increase in cardiac output.<sup>4,7</sup> In subjects, who show an increase in peak velocity (0.6 m/s), stroke volume (20%), or mean transvalvular pressure gradient (10 mm Hg) with DSE have LV contractile reserve. Patients with true severe AS and evidence of CR have a clear indication for AVR. The possible response patterns to dobutamine in patients with LF/LGAS are summarized in **Table 3**.

DeFilippi et al.<sup>15</sup> demonstrated that DSE could be used to distinguish individuals with fixed AS from those with pseudo-AS. In patients with fixed AS, dobutamine induced an increase in peak velocity, mean transvalvular pressure gradient, and valve resistance and no change in valve area. In contrast, in those with pseudo-AS, dobutamine caused a considerable increase in valve area (0.3 cm<sup>2</sup>) without a substantial change in peak velocity, mean transvalvular pressure gradient, or valve resistance.

### **DISTINGUISHING BETWEEN TRUE SEVERE AND PSEUDOSEVERE AORTIC STENOSIS**

The evaluation of the changes in EOA and gradient during dobutamine infusion are also helpful in differentiating true severe from pseudosevere AS. Typically, pseudosevere AS shows an increase in EOA and relatively little increase in gradient in response to increasing flow, whereas true severe AS is characterized by little or no increase in EOA and an

increase in gradient that is congruent with the relative increase in flow. Several parameters and criteria have been proposed in the literature to identify patients with pseudosevere AS during DSE, including a peak stress mean gradient 30 or 40 mm Hg depending on studies, a peak stress EOA 1.0 or 1.2 cm<sup>2</sup>, and/or an absolute increase in EOA 0.3 cm<sup>2</sup>.<sup>15,16,22,26,28,30</sup> thus, the optimal cut-off values remain to be determined. The prevalence of pseudosevere AS is reported to be between 20% and 30%.<sup>15,26,28,31</sup>

Some patients may nonetheless have an ambiguous response to DSE due to variable increases in flow<sup>15,26,27</sup> and interpreting the changes in EOA and gradients without considering the relative changes in flow may often be problematic. Hence, to overcome this limitation, the investigators of the TOPAS (Truly or Pseudo-Severe Aortic Stenosis) study proposed to calculate the projected EOA that would have occurred at a standardized flow rate of 250 mL/s (EOAProj)<sup>26,27</sup> and this new parameter has been shown to be more closely related to actual AS severity, impairment of myocardial blood flow, LV flow reserve, and survival than the traditional DSE parameters.<sup>5,26,27,32</sup> Patients with no increase in stroke volume may nonetheless have an increase in mean flow rate sufficient to allow a reliable measurement of EOAProj; this is due to shortening of LV ejection time in relation to an increase in heart rate.<sup>26,27</sup> However, there are 10–20% of patients in whom the increase in flow rate is insufficient to allow calculation of EOAProj. In such cases or those with ambiguous results during DSE, quantification of valve calcification by multislice computed tomography may also be useful.

Therefore, DSE clearly can help to differentiate patients with fixed low-gradient AS from those with pseudo-AS.

In the study of Quere et al.<sup>17</sup> published in *Circulation*, the operative mortalities for those with and without LV contractile reserve were 6% and 33%, respectively.

From a previously reported French multicenter trial,<sup>16</sup> Quere et al.<sup>17</sup> identified 66 patients with symptomatic AS, a mean transvalvular pressure gradient 40 mm Hg, and an LVEF 40% who survived valve replacement surgery and underwent an evaluation of functional status and LVEF postoperatively. It was found that most patients with severe AS and a low transvalvular pressure gradient manifested a substantial improvement in symptomatic status and LVEF after valve replacement surgery, and these improvements occurred with similar frequency in subjects with and without LV contractile reserve.

### **Normal Left Ventricular Contractility and Low-gradient Severe Aortic Stenosis**

The above term is reserved for patients with normal left ventricular ejection fraction but with reduced stroke volume and reduced systolic function seen secondary to left ventricular hypertrophy secondary to aortic stenosis known as increased concentric hypertrophy (ICR). This ICR in turn leads to



decreased LV filling and reduced stroke volume (SV). Lower SV results in lower gradients across aortic valve.<sup>18</sup>

Inaccurate measurements and underestimation can occur due to LVOT shape which can alter the calculation of SV and AVA. This in turn can lead to inconsistent measurement of Severity of AS.<sup>19</sup> It is here that role of TEE becomes important for planimetry of aortic valve.

Role of tissue Doppler imaging is important as it there would be impaired long axis shortening with reduced contractility. It was concluded in SEAS substudy<sup>20</sup> that LV myocardial systolic dysfunction is common in asymptomatic AS in particular in patients with low-flow AS and increased valvuloarterial afterload, whereas EF is generally preserved. A condition similar to LF-LGAS was seen in these patients with low SV and transaortic gradients. The major concern in these cases is that underestimation of AVA can lead to underutilization of valve replacement.<sup>11</sup>

Hachicha<sup>11</sup> et al described ventriculoarterial impedance (Zva), an index of global hemodynamic load and related this to the onset of symptoms and adverse events.

$$\text{Ventriculoarterial impedance (Zva)} = \frac{\text{Systolic arterial pressure} + \text{mean net transaortic gradient}}{\text{Stroke volume/m}^2}$$

Height can be substituted instead of BSA if SV is indexed to height in this formula. A value of Zva  $\geq 4.5$  mm Hg/mL m<sup>2</sup> may be useful to identify patients who are at risk of deterioration of myocardial function as per previously reported studies.<sup>20,21</sup>

Normal LVEF does not mean normal SV. Hachicha et al<sup>11</sup> showed that one-third of patients with severe AS had reduced SV Index (SV/BSA  $<35$  mL/m<sup>2</sup>) despite preserved LVEF. This will lead to low flow situation and which in turn leads to low transvalvular gradients. In their study of 512 consecutive patients with echocardiographically determined low gradient severe AS (AVA  $\leq 0.6$  cm<sup>2</sup>/m<sup>2</sup>) and LVEF  $\geq 50\%$ , Hachicha et al<sup>11</sup> concluded that normal flow (NF) having SV index  $\geq 35$  mL was seen in 65% of cases and paradoxically low flow (PLF) having SV index  $\leq 35$  mL in 35% of cases. During 5 year follow-up, patients with PLF had a reduced survival compared to those with NF.

Guidelines<sup>22</sup> regarding diagnostic and therapeutic recommendations for LF-LGAS. Further prospective studies are needed to determine the prognosis and most appropriate timing of AVR in these asymptomatic paradoxically LF-LGAS patients with preserved LV function.

In clinical practice we are not infrequently challenged by the reality of patients with severe AS by both valve appearance and calculated valve area (AVA  $<1$  cm<sup>2</sup>) and who present with a mean gradient in the mild-to-moderate range ( $<40$  mm Hg) despite normal LV contractility. Obviously, technical errors have to be excluded, but this possible presentation of severe AS has recently been increasingly recognized<sup>8-11</sup> and has been described in up to 42% of patients with severe AS and normal LV contractility. Importantly, these patients do not

seem to have a better prognosis than their 'high-gradient' counterparts.<sup>9-11</sup> Possible explanations for this hemodynamic pattern include:<sup>9-11</sup>

- Relatively low stroke volume, which is not suggested by an apparently normal EF—this could be related to small LV cavity (small-sized patients, severely hypertrophic ventricles) or occult L systolic dysfunction (elderly patients, LV hypertrophy); and
- Higher systemic vascular resistance and LV afterload. The importance of recognizing this not uncommon hemodynamic pattern cannot be overemphasised, since AVR, when appropriate, should not be denied to these patients due to a possibly misleading 'not severe enough' gradient.

## CONCLUSION

Echocardiography is the first-line diagnostic tool in the assessment of patients with AS. Cut-off values define severity criteria used to decide appropriateness of intervention. A large number of patients do not fulfill all accepted criteria and may present with perplexing hemodynamic patterns and echocardiographic results. Awareness of the sources of possible errors and of less typical echocardiographic results is essential for the correct management of AS patients whose echocardiographic studies are, apparently, confounding.

## REFERENCES

1. Briand M, Dumesnil JG, Kadem L. Reduced systemic arterial compliance impacts significantly on left ventricular afterload and function in aortic stenosis: implications for diagnosis and treatment. *J Am Coll Cardiol.* 2005;46:291-8.
2. Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. *Eur J Echocardiogr.* 2009;10:1-25.
3. Minners J, Allgeier M, Gohlke-Baerwolf C, et al. Inconsistencies of echocardiographic criteria for the grading of aortic valve stenosis. *Eur Heart J.* 2008;29(8):1043-8.
4. Tribouilloy C, Levy F, Rusinaru D, et al. Outcome after aortic valve replacement for low-flow/low-gradient aortic stenosis without contractile reserve on dobutamine stress echocardiography. *J Am Coll Cardiol.* 2009;53:1865-73.
5. Clavel MA, Fuchs C, Burwash IG, et al. Predictors of outcomes in low-flow, low-gradient aortic stenosis: results of the multicentre TOPAS Study. *Circulation.* 2008;118:S234-42.
6. Chenzbraun A, et al. *Am J Cardiol.* 2003;92(12):1451-4.
7. Bermejo J, Yotti R. Low-gradient aortic valve stenosis. Value and limitations of dobutamine stress testing. *Heart.* 2007;93:298-302.
8. Dumesnil JG, Pibarot P, Carabello B. Paradoxical low flow and/or low gradient severe aortic stenosis despite preserved left ventricular ejection fraction: implications for diagnosis and treatment. *Eur Heart J.* 2010;31(3):281-9.
9. Flachskampf FA. Severe aortic stenosis with low gradient and apparently preserved left ventricular systolic function—under-recognized or overdiagnosed? *Eur Heart J.* 2008;29(8):966-8.

10. Barasch EI, Fan D, Chukwu EO, et al. Severe isolated aortic stenosis with normal left ventricular systolic function and low transvalvular gradients: pathophysiologic and prognostic insights. *J Heart Valve Dis.* 2008;17(1):81-8.
11. Hachicha Z, Dumesnil JG, Bogaty P. Paradoxical low flow, low gradient severe aortic stenosis despite preserved ejection fraction is associated with higher after load and reduced survival. *Circulation.* 2007;115:2856-64.
12. Burwash IG, Thomas DD, Sadahiro M, Pearlman AS, Verrier ED, Thomas R, Kraft CD, Otto CM. Dependence of Gorlin formula and continuity equation valve areas on transvalvular volume flow rate in valvular aortic stenosis. *Circulation.* 1994;89:827-35.
13. Cannon SR, Richards KL, Crawford M. Hydraulic estimation of stenotic orifice area: a correction of the Gorlin formula. *Circulation.* 1985;71:1170-8.
14. Cannon JD, Zile MR, Crawford FA Jr, Carabello BA. Aortic valve resistance as an adjunct to the Gorlin formula in assessing the severity of aortic stenosis in symptomatic patients. *J Am Coll Cardiol.* 1992;20:1517-23.
15. deFilippi CR, Willett DL, Brickner ME, Appleton CP, Yancy CW, Eichhorn EJ, Grayburn PA. Usefulness of dobutamine echocardiography in distinguishing severe from non-severe valvular aortic stenosis in patients with depressed left ventricular function and low transvalvular gradients. *Am J Cardiol.* 1995;75:191-4.
16. Monin JL, Quere JP, Monchi M, Petit H, Baleynaud S, Chauvel C, Pop C, Ohlmann P, Lelguen C, Dehant P, Tribouilloy C, Gueret P. Low gradient aortic stenosis: operative risk stratification and predictors for long-term outcome: a multicenter study using dobutamine stress hemodynamics. *Circulation.* 2003;108:319-24.
17. Quere JP, Monin JL, Levy F, Petit H, Baleynaud S, Chauvel C, Pop C, Ohlmann P, Lelguen C, Dehant P, Gueret P, Tribouilloy C. Influence of preoperative left ventricular contractile reserve on postoperative ejection fraction in low-gradient aortic stenosis. *Circulation.* 2006;113:1738-44.
18. Jander Nikolaus. Low-gradient 'severe' aortic stenosis with preserved ejection fraction: new entity, or discrepant definitions? *Eur Heart J.* 2008;10(Suppl E):E11-E15.
19. Minners J, Allegeier M, Gohlke-Baerwolf C. Inconsistencies of echocardiographic criteria for the grading of aortic valve stenosis. *Eur Heart J.* 2008;29:1043-8.
20. Cramariue Dana, Cioffi Giovanni, Ashild E. Low-flow aortic stenosis in asymptomatic patients. *JACC: Cardiovasc Imaging.* 2009;2:390-99.
21. Briand M, Dumesnil JG, Kaedm L. Reduced systemic arterial compliance impacts significantly on left ventricular afterload and function in aortic stenosis: implications for diagnosis and treatment. *J Am Coll Cardiol.* 2005;46:291-8.
22. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012): The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J.* 2012;33:2451-96.
23. Bonow RO, Carabello BA, Chatterjee K, et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* 2008;52:e1-142.
24. Connolly HM, Oh JK, Schaff HV, et al. Severe aortic stenosis with low transvalvular gradient and severe left ventricular dysfunction. Result of aortic valve replacement in 52 patients. *Circulation.* 2000;101:1940-6.
25. Schwammenthal E, Vered Z, Moshkowitz Y, et al. Dobutamine echocardiography in patients with aortic stenosis and left ventricular dysfunction: predicting outcome as a function of management strategy. *Chest.* 2001;119:1766-77.
26. Blais C, Burwash IG, Mundigler G, et al. Projected valve area at normal flow rate improves the assessment of stenosis severity in patients with low flow, low-gradient aortic stenosis: the multicentre TOPAS (Truly or Pseudo Severe Aortic Stenosis) study. *Circulation.* 2006;113:711-21.
27. Clavel MA, Burwash IG, Mundigler G, et al. Validation of conventional and simplified methods to calculate projected valve area at normal flow rate in patients with low flow, low gradient aortic stenosis: the multicenter TOPAS (True or Pseudo Severe Aortic Stenosis) study. *J Am Soc Echocardiogr.* 2010;23:380-6.
28. Nishimura RA, Grantham JA, Connolly HM, Schaff HV, Higano ST, Holmes DR Jr. Low-output, low-gradient aortic stenosis in patients with depressed left ventricular systolic function: the clinical utility of the dobutamine challenge in the catheterization laboratory. *Circulation.* 2002;106:809-13.
29. Carabello BA, Green LH, Grossman W, Cohn LH, Koster JK, Collins JJ Jr. Hemodynamic determinants of prognosis of aortic valve replacement in critical aortic stenosis and advanced congestive heart failure. *Circulation.* 1980;62:42-8.
30. Zuppiroli A, Mori F, Olivetto I, Castelli G, Favilli S, Dolara A. Therapeutic implications of contractile reserve elicited by dobutamine echocardiography in symptomatic, low-gradient aortic stenosis. *Ital Heart J.* 2003;4:264-70.
31. Fougères É, Tribouilloy C, Monchi M, et al. Outcomes of pseudosevere aortic stenosis under conservative treatment. *Eur Heart J.* 2012;33(19):2426-33.
32. Burwash IG, Lortie M, Pibarot P, et al. Myocardial blood flow in patients with low flow, low gradient aortic stenosis: differences between true and pseudo-severe aortic stenosis. Results from the multicenter TOPAS (Truly or Pseudo-Severe Aortic Stenosis) Study. *Heart.* 2008;94:1627-33.
33. Rick A Nishimura, Catherine M Otto, Robert O Bonow, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* 2014;63(22):2438-88.



# Cardiac Imaging Update 2017

## Salient Features

- It is a unique blend of cardiovascular diagnostic and prognostic imaging and the appropriateness of clinical and procedural management
- Covers the full range of clinical cardiac imaging and its applications, focusing on how the information derived can be used in clinical decision-making and patient management as well as current topics in clinical cardiology
- Focuses on its major areas of strength with chapters on endocarditis, aortic stenosis, heart failure, and cardiomyopathy; covers the recent developments in speckle tracking; the applications of cardiovascular magnetic resonance (CMR)
- Discusses the relative roles of CMR and cardiac CT
- Explores invasive approaches to assessment of coronary plaque and flow physiology
- Provides a comprehensive update of the status of the clinical applications of the imaging approaches as well as an update of important issues of clinical cardiology
- Serves as a soapbox to encourage the development of an integrated cardiovascular imaging subspecialty

**GN Mahapatra** is Senior Consultant and Head, Department of Nuclear Medicine, PET-CT and SPECT-CT, SevenHills Hospital, Mumbai, Maharashtra, India, for the last 34 years. He is the Founder and Past President of the Nuclear Cardiological Society of India (NCSI). He has had a considerable international exposure to hone his skills that includes training in recent advancements in nuclear medicine, organized by the International Atomic Energy Agency (IAEA), Vienna, Austria, in collaboration with the WHO; Massachusetts General Hospital (MGH), Boston, USA; Middlesex Hospital, UK; Cedars-Sinai Medical Center, Los Angeles, USA; the University of Texas; and, MD Anderson Cancer Center, Houston, USA. He has published over 150 scientific research and clinical articles in various national and international journals. He has presented over 250 scientific papers at the national and international conferences. He has delivered over 150 guest lectures in various societies' annual conferences, such as the Cardiological Society of India (CSI), Association of Physicians of India (API), Indian Academy of Echocardiography, Indian College of Cardiology, Society of Nuclear Medicine (India), and American College of Cardiology (ACC). He has contributed many chapters in the books CSI Update, API Update, Textbook on History of Cardiology and, very recently, Atrial Fibrillation Update: A Textbook of Cardiology. He has been bestowed upon with various prestigious national awards, such as the 'Vikram Sarabhai Oration Award' by the Society of Nuclear Medicine, India, at the 43rd Annual Conference of the Society, in 2011; and, 'KK Datey Memorial Oration Award', at the 66th Annual Conference of the Cardiological Society of India (CSI), in 2014. He received the Doctor of Science (DSc), honoris causa, from the Ravenshaw University, Cuttack, Odisha, India, in the 7th Convocation Ceremony, in 2014. He was invited as an International Guest Faculty to deliver guest lecture at the 63rd ACC Congress in Washington DC, in 2014; and, Biennial Congress of South African Society (SASNM), Johannesburg, in 2016.



**PC Manoria** is the Director, Manoria Heart and Critical Care Hospital, Bhopal, Madhya Pradesh, India, and Former Professor and Head, Department of Cardiology, Gandhi Medical College, Bhopal. He has a distinguished academic career. He has a great clinical acumen and is an unmatched specialist with an in-depth knowledge of other subspecialties of medicine too. He has been bestowed upon with several awards and orations, such as Lifetime Achievement Award in Clinical and Preventive Cardiology by Hon'ble Shri APJ Abdul Kalam, Past President of India; Lifetime Achievement Award by the Indian Federation of Ultrasound in Medicine and Biology; and, Netaji Oration Award of API, etc. He has been the National President of nearly all prestigious associations, including the Association of Physicians of India, and Cardiological Society of India. He is also Past Chairman, Hypertension Council, Asian Pacific Society of Cardiology; and, Past Vice President, SAARC Cardiac Society. He has edited 28 books on diverse aspects in medicine and cardiology, and has 70 publications to his credit.



**Diwakar Jain** is a Professor of Medicine (Cardiovascular Medicine) and the Director of Nuclear Cardiology Laboratory at New York Medical College, USA. He attended Medical College, Rohtak, Haryana, India, and underwent residency and fellowship training in medicine and cardiology at Postgraduate Institute of Medical Education and Research, Chandigarh, India. He underwent further training in cardiology at Northwick Park Hospital and Clinical Research Centre, Harrow, UK; and, Yale University School of Medicine, USA. He has conducted research in the fields of molecular imaging, cardiotoxicity of cancer chemotherapy; and, behavior, mental stress, and heart disease. He has published over 150 scientific papers, book chapters, editorials and review articles, and 2 books also.



Available at all medical bookstores  
or buy online at [www.jaypeebrothers.com](http://www.jaypeebrothers.com)



**JAYPEE BROTHERS**  
**Medical Publishers (P) Ltd.**  
[www.jaypeebrothers.com](http://www.jaypeebrothers.com)

Join us on [f facebook.com/JaypeeMedicalPublishers](https://www.facebook.com/JaypeeMedicalPublishers)

Shelving Recommendation  
**CARDIOLOGY**

ISBN 978-93-86322-93-7



9 789386 322937